Huawei, OpenAI, ByteDance Race Into AI Drug Discovery: what are the key facts?

In December 2025, Huawei formed a pharmaceutical unit, positioning itself as an AI enabler for the drug industry rather than a drugmaker or pipeline owner.

Huawei, OpenAI, ByteDance Race Into AI Drug Discovery: what are the key facts?

OpenAI released its life sciences model GPT-Rosalind in April and established a strategic partnership with Novo Nordisk.

Huawei, OpenAI, ByteDance Race Into AI Drug Discovery: what are the key facts?

Anthropic acquired Coefficient Bio, an AI biotech startup with fewer than 10 employees, for $400 million.

Huawei, OpenAI, ByteDance Race Into AI Drug Discovery: what are the key facts?

In June, ByteDance spun off its AI drug discovery business as Anew Labs, which closed a $290 million first funding round three months later.

Huawei, OpenAI, ByteDance Race Into AI Drug Discovery: what are the key facts?

No drug fully designed by AI has yet completed Phase III clinical trials and won marketing approval anywhere in the world.

Physix Frontier · News Briefing Card (enbrief · Nov 9, 2026)

Huawei, OpenAI, ByteDance Race Into AI Drug Discovery

KEY FACTS

In December 2025, Huawei formed a pharmaceutical unit, positioning itself as an AI enabler for the drug industry rather than a drugmaker or pipeline owner.
OpenAI released its life sciences model GPT-Rosalind in April and established a strategic partnership with Novo Nordisk.
Anthropic acquired Coefficient Bio, an AI biotech startup with fewer than 10 employees, for $400 million.
In June, ByteDance spun off its AI drug discovery business as Anew Labs, which closed a $290 million first funding round three months later.
No drug fully designed by AI has yet completed Phase III clinical trials and won marketing approval anywhere in the world.

KEY DATA

$2.1 billionIsomorphic Labs Series B funding

$40-50 billionIsomorphic Labs valuation

About $1.5 billionAnew Labs post-money valuation

2 to 4 timesAI preclinical R&D efficiency gain

PHYSIX OBSERVATION

Tech giants are crowding into AI drug discovery for the drug industry's vast market space and AI's cost and efficiency gains in the preclinical stage. But AI's advantage drops off a cliff in Phase II trials, showing that human biological complexity remains an insurmountable barrier. In the near term, the shovel-selling enabler role is more realistic than making drugs in-house, and the industry must guard against misreading preclinical efficiency gains as a wholesale disruption of the pharmaceutical paradigm.

Source: enbrief original report ↗